SCHEMBL31005293

SCHEMBL31005293

CCCC[C@H](N)C(=O)N(I)[C@@H](CCC(=O)O)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A2 P43004 4/20 0.44
SLC1A1 P43005 4/20 0.44
SLC1A3 P43003 3/20 0.44
GRIK1 P39086 4/20 0.41
GRIK2 Q13002 4/20 0.41
GRM8 O00222 1/20 0.41
GRM6 O15303 1/20 0.41
GRIN2D O15399 1/20 0.41
GRIN3B O60391 1/20 0.41
GSR P00390 1/20 0.41
CYP1A2 P05177 1/20 0.41
GRM5 P41594 1/20 0.41
GRIA1 P42261 1/20 0.41
GRIA2 P42262 1/20 0.41
GRIA3 P42263 1/20 0.41
GRIA4 P48058 1/20 0.41
GRIN1 Q05586 1/20 0.41
GRIN2A Q12879 1/20 0.41
GRIK3 Q13003 1/20 0.41
GRIN2B Q13224 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30297109 0.81 CYP1A2 (0.46) SLC1A2SLC1A1SLC1A3GRIK1GRIK2
Glutamic Acid SCHEMBL4234323 0.76 SLC1A2 (0.72) SLC1A2SLC1A1SLC1A3GRIK1GRIK2
Glutamic Acid SCHEMBL16859356 0.76 SLC1A2 (0.72) SLC1A2SLC1A1SLC1A3GRIK1GRIK2
Glutamic Acid SCHEMBL4234382 0.76 SLC1A2 (0.72) SLC1A2SLC1A1SLC1A3GRIK1GRIK2
SCHEMBL17983515 0.75 NOD1 (0.44) SLC1A2SLC1A1SLC1A3GRIK1GRIK2
SCHEMBL4980487 0.72 CYP1A2 (0.43) SLC1A2SLC1A1SLC1A3GRIK1GRIK2
SCHEMBL34471252 0.71 FFAR4 (0.43) SLC1A2SLC1A1GRIK1GRIK2GSR
SCHEMBL32663027 0.71 SLC1A2 (0.47) SLC1A2SLC1A1SLC1A3GRIK1GRIK2
SCHEMBL844867 0.70 DPP4 (0.49) SLC1A2SLC1A1SLC1A3GRIK1GRIK2
SCHEMBL844868 0.70 DPP4 (0.49) SLC1A2SLC1A1SLC1A3GRIK1GRIK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240376170-A1 CONDITIONALLY ACTIVATED PROTEINS AND METHODS OF USE BRIGHT PEAK THERAPEUTICS AG (CH) 2024-11-14 US disclosed
WO-2024150174-A1 CONDITIONALLY ACTIVATED IMMUNOCYTOKINES AND METHODS OF USE BRIGHT PEAK THERAPEUTICS AG (CH) 2024-07-18 WO disclosed
WO-2024150172-A1 CLEAVABLE PEPTIDES AND METHODS OF USE THEREOF BRIGHT PEAK THERAPEUTICS AG (CH) 2024-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240376170-A1 CONDITIONALLY ACTIVATED PROTEINS AND METHODS OF USE SPPL2A, IL2, CPB2 SLC1A2 4547/4885SLC1A1 4795/4885SLC1A3 4725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.